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Introduction: Chronic rhinosinusitis (CRS) with nasal
polyps is a common form of the disorder with distinct
immunopathology and significant impact on the health-
related quality of life of patients. Several treatment
options—depending on the clinical course and severity of
the disease—have been recommended, from medical
therapy with oral or topical corticosteroids to various
methods of surgical management. Short courses of oral
steroids have been recommended and used in clinical
practice, usually by specialists in patients with severe
CRS with nasal polyps and for management of severe
exacerbations of the symptoms with which these patients
present. Several studies demonstrated that such treatment
results in rapid symptomatic improvement and in shrinking
of nasal polyps (pharmacologic polypectomy) in most
patients. However, the long-term effects of a short course
of oral steroid therapy for CRS with nasal polyps have not
been studied in randomized controlled trials.
Aims: The aim of this study was to assess whether initial
therapy with oral steroids would lead to greater and sustained
reduction in polyp size and greater improvement in symp-
toms, nasal airflow, and quality of life during the follow-up
treatment with topical steroids.
Methods: Adult patients with CRS associated with nasal
polyps were recruited from a single-center specialty clinic
based on the presence of bilateral moderate- to large-sized
nasal polyps (grade >1 according to Lildholdt scale) and
typical symptoms of CRS, including anterior or postnasal
discharge, nasal obstruction, and decreased sense of smell
for more than 12 weeks. Patients who had been treated with
oral steroids in the past 3 months, had sinus surgery in the
past year, or had significant mechanical nasal airway
obstruction due to septal deviation were excluded. After a
2-week run-in period without use of CRS/nasal polyposis
medications, patients were randomly assigned to receive
oral prednisolone, 25 mg/d, or placebo in identical tablets
for 2 weeks. Then, patients in both groups received
fluticasone propionate nasal drops, 400 μg twice daily, for
8 weeks, and then fluticasone nasal spray, 200 μg twice
daily, for an additional 18 weeks. No other medications for
rhinitis were permitted during the study.
The primary outcome measure was nasal endoscopic
polyp grading performed by two independent, study-
blinded investigators, who assessed standard video sequen-
ces stored on the computer. Secondary efficacy outcome
measures included subjective (visual analogue scale) and
objective (smell test) assessment of olfaction, symptom
scores, peak inspiratory flow, and rhinitis-related quality of
life. Safety measures included urinary and serum cortisol
level measurements, low-dose adrenocorticotropic stimula-
tion test, and markers of bone turnover.
All primary and secondary outcomes and safety measures
were assessed at randomization and after each treatment
period: 2, 20, and 28 weeks from randomization.
Results: Of the 118 patients screened, 60 were randomly
assigned, and 51 completed the study. Baseline character-
istics with respect to demographics, disease duration,
airway inflammation, airway obstruction, and indices of
severity were similar in both groups, and only a few
randomly assigned patients (four in the placebo arm, three
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corticosteroids (6–24 months before the study).
Patients taking oral prednisolone, but not those receiving
placebo, demonstrated a significant mean decrease in the
polyp grade frombaseline to 2 weeks .The difference inpolyp
size between those in the oral corticosteroid group and those
receiving placebo was still visible at 10 weeks but was not
significantatweek28oftreatment(althoughatthistimepoint,
both groups had significantly decreased polyp size compared
with baseline). Similarly, hyposmia assessed by visual
analogue scale improved significantly in the oral steroid
groupat2weeksandwasstillsignificantlybetterascompared
withthe placebo group after 10weeks, but not after 18 weeks.
The smell test score improvement observed after 2 weeks in
the oral corticosteroid group was maintained up to week 28 of
the study, although the difference between this group and the
placebo group was significant only after 2 weeks.
Interestingly, in the placebo group, sense of smell as
assessed by both visual analogue scale and smell test was
improved after administration of intranasal drop (at
10 weeks) but almost returned to baseline value after
treatment with nasal spray (at 28 weeks).
The mean Total Nasal Symptom Score and closely related
Rhinitis Quality of Life score, although they were significant-
ly better in the oral corticosteroid group after 2 weeks, were
decreased to a similar extent in both the placebo and oral
corticosteroid group after 10 and 28 weeks. In total, 25
patients (83%) in the oral corticosteroid group improved by
more than the minimal important difference in polyp grade or
hyposmia at the end of 28 weeks, as compared with only 17
patients (57%) in the placebo group.
Basalanddynamicadrenalfunctionweresuppressedbyoral
prednisolone at 2 weeks but returned to normal values after 10
and 28 weeks. Similarly, markers of osteoblast activity, which
deceased after 2 weeks, returned to normal values at 10 weeks.
Discussion: In this study, the authors demonstrated that a 2-
week course of oral steroid therapy, in addition to exerting
rapid effects on symptoms of CRS with nasal polyps, had a
long-term effect extending beyond the time of treatment. In
most patients with CRS with nasal polyps, a burst of 25 mg of
oral prednisolone followed by intranasal steroids was gener-
ally more effective than topical therapy alone in decreasing
polyp size and improving sense of smell over 20 weeks of
observation. A short course of oral steroids turned out to be
safe, as after transient suppression of adrenal function and an
increase in bone turnover, these safety parameters returned to
baseline at 10 weeks. In practical terms, the study demon-
strated that a short course of oral corticosteroids could be
recommended for most patients with moderate to severe CRS
with nasal polyps as an initial therapy if subsequent chronic
treatment with topical steroids is planned.
However,TotalNasalSymptomScores,RhinitisQualityof
Life scores, as well as an objective measurement of nasal
obstruction (peak nasal inspiratory flow) at 10 and 28 weeks
of the study were improved to a similar extent in patients
receiving placebo or an initial course of oral corticosteroids,
suggesting limited efficacy of the proposed treatment regi-
men. One cannot dispute that pretreatment with a higher dose
of oral corticosteroids or extension of the treatment beyond
2 weeks, as recommended by some guidelines, could result in
better long-term effects, including the effect on nasal
symptoms and objective measures of nasal obstruction.
Comments
One limitation of the study is the relatively small number of
patients and possible selection bias, as out of 118 patients
screened, only 60 were randomly assigned, 51 of whom
completed the study (ie, 43% of screened population).
Furthermore, lack of objective assessment of the sinus mucosal
hypertrophy (with CT scans or nuclear magnetic resonance)
bothatbaselineandat follow-up,does not allowfor comparison
of changes in the mucosal hypertrophy in both groups.
In conclusion, this randomized controlled study of the
long-term effects of initial therapy with a short course of
oral steroids is of practical value, showing efficacy and
safety of such a treatment regimen. The study results may
encourage use of such a treatment regimen in clinical
practice, especially in patients with unsatisfactory response
to intranasal corticosteroids.
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